AtriCure (ATRC) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed AtriCure (ATRC) over the past year, gaining 150.7% versus a gain of 50.6%. Over five years, PLSE leads with a +130.9% price change compared with -26.0% for ATRC. Pulse Biosciences is the larger company by market cap ($3.56 billion vs $2.69 billion), about 1.3 times the size.
AtriCure converts more of its revenue into profit, with a net margin of -2.1% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | PLSE |
|---|---|---|
| Share price | $52.84 | $49.98 |
| Market cap | $2.69B | $3.56B |
| 1-day change | -0.88% | +1.81% |
| YTD return | +33.57% | +264.02% |
| 1-year return | +50.63% | +150.65% |
| 5-year return | -25.96% | +130.85% |
| P/E ratio (TTM) | 251.62 | — |
| Forward P/E | 121.76 | — |
| EPS (TTM) | $0.21 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $350.00K |
| Revenue growth (YoY) | +14.88% | — |
| Net income (latest FY) | $-11.45M | $-72.78M |
| Gross margin | 74.98% | -54.00% |
| Operating margin | -1.77% | -21982.57% |
| Net margin | -2.14% | -20794.57% |
| 52-week high | $61.70 | $58.90 |
| 52-week low | $25.36 | $12.56 |
| Distance from 52-week high | -14.36% | -15.14% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +3.88% | +13.05% |
| Average volume | 1.08M | 502.81K |
| Shares outstanding | 50.87M | 71.32M |
| Employees | 1,350 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLSE has outperformed ATRC by 100.0 percentage points over the past year.
- AtriCure is more profitable, keeping -2.1 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
ATRC vs PLSE FAQ
Which is bigger, AtriCure or Pulse Biosciences?
Pulse Biosciences (PLSE) is larger, with a market capitalization of $3.56B compared with $2.69B for AtriCure (ATRC).
Which stock has performed better over the past year, ATRC or PLSE?
PLSE returned +150.65% over the past 12 months, compared with +50.63% for ATRC (price return, excluding dividends). Past performance does not predict future results.
Are AtriCure and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.